Viveve Medical (VIVE) Now Covered by Northland Securities

Northland Securities started coverage on shares of Viveve Medical (NASDAQ:VIVE) in a research note issued to investors on Friday. The firm set an “outperform” rating and a $8.00 price target on the stock. Northland Securities’ price target points to a potential upside of 60.97% from the stock’s current price.

A number of other equities analysts have also recently issued reports on VIVE. Cowen set a $11.00 price objective on Viveve Medical and gave the stock a “buy” rating in a report on Monday, October 23rd. Mizuho initiated coverage on Viveve Medical in a report on Thursday, November 16th. They issued a “buy” rating and a $10.00 price objective for the company. Finally, ValuEngine cut Viveve Medical from a “sell” rating to a “strong sell” rating in a report on Friday, December 1st. One analyst has rated the stock with a sell rating and six have issued a buy rating to the company. Viveve Medical currently has an average rating of “Buy” and an average price target of $10.00.

Viveve Medical (VIVE) traded down $0.22 on Friday, hitting $4.97. The stock had a trading volume of 250,000 shares, compared to its average volume of 138,267. Viveve Medical has a 1 year low of $3.75 and a 1 year high of $11.16. The company has a debt-to-equity ratio of 2.72, a current ratio of 3.89 and a quick ratio of 3.63. The stock has a market cap of $96.55, a PE ratio of -2.31 and a beta of -0.67.

Viveve Medical (NASDAQ:VIVE) last posted its quarterly earnings data on Wednesday, November 8th. The company reported ($0.50) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.42) by ($0.08). Viveve Medical had a negative return on equity of 275.77% and a negative net margin of 257.58%. The firm had revenue of $4.07 million during the quarter, compared to analysts’ expectations of $4.10 million. During the same quarter in the previous year, the company posted ($0.46) earnings per share. Viveve Medical’s revenue for the quarter was up 120.1% compared to the same quarter last year. research analysts expect that Viveve Medical will post -2.04 EPS for the current fiscal year.

Several institutional investors and hedge funds have recently bought and sold shares of VIVE. Rhumbline Advisers purchased a new stake in Viveve Medical during the 2nd quarter valued at about $110,000. JPMorgan Chase & Co. purchased a new stake in Viveve Medical during the 2nd quarter valued at about $151,000. Virtu KCG Holdings LLC purchased a new stake in Viveve Medical during the 2nd quarter valued at about $169,000. Schwab Charles Investment Management Inc. purchased a new stake in Viveve Medical during the 2nd quarter valued at about $189,000. Finally, California State Teachers Retirement System purchased a new stake in Viveve Medical during the 2nd quarter valued at about $190,000. Hedge funds and other institutional investors own 66.90% of the company’s stock.

WARNING: This report was first published by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are viewing this report on another domain, it was stolen and reposted in violation of US & international trademark and copyright law. The original version of this report can be accessed at https://www.chaffeybreeze.com/2018/01/05/viveve-medical-vive-now-covered-by-northland-securities.html.

Viveve Medical Company Profile

Viveve Medical, Inc designs, develops, manufactures and markets a medical device, Geneveve, for the non-invasive treatment of vaginal laxity, for improved sexual function, and for vaginal rejuvenation. The Company’s, Geneveve, is a non-invasive solution for vaginal laxity, which includes three components: the Viveve System (a radio frequency (RF), generator housed in a table-top console), a reusable handpiece and a single-use treatment tip, as well as several other consumable accessories.

Analyst Recommendations for Viveve Medical (NASDAQ:VIVE)

Receive News & Ratings for Viveve Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viveve Medical and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply